Lemur tyrosine kinase-2 signalling regulates kinesin-1 light chain-2 phosphorylation and binding of Smad2 cargo

Oncogene

Volumn 31, Issue 22, 2012, Pages 2773-2782

  Manser, C ^a   Guillot, F ^a   Vagnoni, A ^a   Davies, J ^a   Lau, K F ^a,b   McLoughlin, D M ^a,c   De Vos, K J ^a   Miller, C C J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c ST PATRICK S HOSPITAL   (Ireland)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Axonal transport; Glycogen synthase kinase 3 ; Protein phosphatase 1C; Transforming growth factor

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; KINESIN 1; KINESIN 1 LIGHT CHAIN 2; LEMUR TYROSINE KINASE 2; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 1C; PROTEIN TYROSINE KINASE; SMAD2 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN TRANSPORT; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; CELL NUCLEUS; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOGEN SYNTHASE KINASE 3; HELA CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; PHOSPHORYLATION; PROTEIN PHOSPHATASE 1; PROTEIN-SERINE-THREONINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TWO-HYBRID SYSTEM TECHNIQUES;

LEMUR;

EID: 84859607330     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.437     Document Type: Article

References (59)

1. Bajaj NP, al-Sarraj ST, Leigh PN, Anderson V, Miller CC. (1999). Cyclin dependent kinase-5 (CDK-5) phosphorylates neurofilament heavy (NF-H) chain to generate epitopes for antibodies that label neurofilament accumulations in amyotrophic lateral sclerosis (ALS) and is present in affected motor neurones in ALS. Prog Neuropsychopharmacol Biol Psychiatry 23: 833-850. (Pubitemid 29416758)
2. Batut J, Howell M, Hill CS. (2007). Kinesin-mediated transport of Smad2 is required for signaling in response to TGF-beta ligands. Dev Cell 12: 261-274. (Pubitemid 46172913)
3. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y et al. (2003). Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 278: 45937-45945. (Pubitemid 37432740)
4. Chibalina MV, Seaman MN, Miller CC, Kendrick-Jones J, Buss F. (2007). Myosin VI and its interacting protein LMTK2 regulate tubule formation and transport to the endocytic recycling compartment. J Cell Sci 120: 4278-4288.
5. Cross DAE, Alessi DR, Cohen P, Andjelkovich M, Hemmings B. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789. (Pubitemid 26004411)
6. DeBoer SR, You Y, Szodorai A, Kaminska A, Pigino G, Nwabuisi E et al. (2008). Conventional kinesin holoenzymes are composed of heavy and light chain homodimers. Biochemistry 47: 4535-4543. (Pubitemid 351522104)
7. De Vos KJ, Grierson AJ, Ackerley S, Miller CCJ. (2008). Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 31: 151-173.
8. Dohadwala M, Da Cruz e Silva EF, Hall FL, Williams RT, Carbonaro-Hall DA, Nairn AC et al. (1994). Phosphorylation and inactivation of protein phosphatase 1 by cyclin-dependent kinases. Proc Natl Acad Sci USA 91: 6408-6412.
9. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK et al. (2008). Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40: 316-321. (Pubitemid 351311772)
10. Fitzgerald LM, Kwon EM, Koopmeiners JS, Salinas CA, Stanford JL, Ostrander EA. (2009). Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features. Clin Cancer Res 15: 3231-3237.
11. Fu AK, Fu WY, Cheung J, Tsim KW, Ip FC, Wang JH et al. (2001). Cdk5 is involved in neuregulin-induced AChR expression at the neuromuscular junction. Nat Neurosci 4: 374-381. (Pubitemid 32260113)
12. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G et al. (2007). Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158. (Pubitemid 46398669)
13. Guidato S, McLoughlin D, Grierson AJ, Miller CCJ. (1998). Cyclin D2 interacts with cdk-5 and modulates cellular cdk-5/p35 activity. J Neurochem 70: 492-500.
14. Guo CY, Brautigan DL, Larner JM. (2002). Ionizing radiation activates nuclear protein phosphatase-1 by ATM-dependent dephosphorylation. J Biol Chem 277: 41756-41761. (Pubitemid 35257484)
15. Harries LW, Perry JR, McCullagh P, Crundwell M. (2010). Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer. BMC Cancer 10: 315.
16. Helps NR, Luo X, Barker HM, Cohen PT. (2000). NIMA-related kinase 2 (Nek2), a cell-cycle-regulated protein kinase localized to centrosomes, is complexed to protein phosphatase 1. Biochem J 349: 509-518. (Pubitemid 30465786)
17. Hernandez F, Langa E, Cuadros R, Avila J, Villanueva N. (2010). Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. Mol Cell Biochem 344: 211-215.
18. Hill CS. (2009). Nucleocytoplasmic shuttling of Smad proteins. Cell Res 19: 36-46.
19. Hirokawa N, Noda Y, Tanaka Y, Niwa S. (2009). Kinesin superfamily motor proteins and intracellular transport. Nat Rev Mol Cell Biol 10: 682-696.
20. Inoue T, Kon T, Ohkura R, Yamakawa H, Ohara O, Yokota J et al. (2008). BREK/LMTK2 is a myosin VI-binding protein involved in endosomal membrane trafficking. Genes Cells 13: 483-495. (Pubitemid 351567049)
21. Katsuno M, Adachi H, Banno H, Suzuki K, Tanaka F, Sobue G. (2011). Transforming growth factor-beta signaling in motor neuron diseases. Curr Mol Med 11: 48-56.
22. Kawa S, Fujimoto J, Tezuka T, Nakazawa T, Yamamoto T. (2004). Involvement of BREK, a serine/threonine kinase enriched in brain, in NGF signalling. Genes Cells 9: 219-232. (Pubitemid 38380229)
23. Kawa S, Ito C, Toyama Y, Maekawa M, Tezuka T, Nakamura T et al. (2006). Azoospermia in mice with targeted disruption of the Brek/Lmtk2 (brain-enriched kinase/lemur tyrosine kinase 2) gene. Proc Natl Acad Sci USA 103: 19344-19349. (Pubitemid 46026033)
24. Kesavapany S, Lau K-F, Ackerley S, Banner S, Shemilt SJA, Cooper JD et al. (2003). Identification of a novel, membrane-associated neuronal kinase, cdk5/p35 regulated kinase (cprk). J Neurosci 23: 4975-4983. (Pubitemid 36793224)
25. Kwon YG, Lee SY, Choi Y, Greengard P, Nairn AC. (1997). Cell cycle-dependent phosphorylation of mammalian protein phosphatase 1 by cdc2 kinase. Proc Natl Acad Sci USA 94: 2168-2173. (Pubitemid 27136846)
26. Lau KF, Chan WM, Perkinton MS, Tudor EL, Chang RC, Chan HY et al. (2008). Dexras1 interacts with FE65 to regulate FE65-amyloid precursor protein dependent transcription. J Biol Chem 283: 34728-34737.
27. Lee MH, Yang HY. (2001). Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 58: 1907-1922.
28. Lew J, Huang Q-Q, Zhong Q, Winkfein RJ, Aebersold R, Hunt T et al. (1994). A brain-specific activator of cyclin-dependent kinase 5. Nature 371: 423-426. (Pubitemid 24302557)
29. Li T, Chalifour LE, Paudel HK. (2007). Phosphorylation of protein phosphatase 1 (PP1) by cyclin-dependent protein kinase 5 during nerve growth factor-induced PC12 cell differentiation. J Biol Chem 282: 6619-6628. (Pubitemid 47100889)
30. Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo J-M et al (1994). Alzheimer's disease-like phosphorylation of the microtubule- associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 4: 1077-1086. (Pubitemid 124001594)
31. Martin K, Steinberg TH, Cooley LA, Gee KR, Beechem JM, Patton WF. (2003). Quantitative analysis of protein phosphorylation status and protein kinase activity on microarrays using a novel fluorescent phosphorylation sensor dye. Proteomics 3: 1244-1255. (Pubitemid 36929546)
32. Massague J. (2008). TGFbeta in cancer. Cell 134: 215-230.
33. Massague J, Gomis RR. (2006). The logic of TGFbeta signaling. FEBS Lett 580: 2811-2820.
34. Massague J, Seoane J, Wotton D. (2005). Smad transcription factors. Genes Dev 19: 2783-2810. (Pubitemid 41739965)
35. McLoughlin DM, Miller CCJ. (1996). The intracellular cytoplasmic domain of the Alzheimer's disease amyloid precursor protein interacts with phosphotyrosine binding domain proteins in the yeast two-hybrid system. FEBS Lett 397: 197-200. (Pubitemid 26414016)
36. Mitsuhashi S, Matsuura N, Ubukata M, Oikawa H, Shima H, Kikuchi K. (2001). Tautomycetin is a novel and specific inhibitor of serine/threonine protein phosphatase type 1, PP1. Biochem Biophys Res Commun 287: 328-331. (Pubitemid 32917599)
37. Mitsuhashi S, Shima H, Tanuma N, Matsuura N, Takekawa M, Urano T et al. (2003). Usage of tautomycetin, a novel inhibitor of protein phosphatase 1 (PP1), reveals that PP1 is a positive regulator of Raf-1 in vivo. J Biol Chem 278: 82-88. (Pubitemid 36043547)
38. Morfini G, Szebenyi G, Brown H, Pant HC, Pigino G, DeBoer S et al. (2004). A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J 23: 2235-2245. (Pubitemid 38833233)
39. Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST. (2002). Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J 21: 281-293. (Pubitemid 34137290)
40. Murakami M, Kawachi H, Ogawa K, Nishino Y, Funaba M. (2009). Receptor expression modulates the specificity of transforming growth factor-beta signaling pathways. Genes Cells 14: 469-482.
41. Noda D, Itoh S, Watanabe Y, Inamitsu M, Dennler S, Itoh F et al. (2006). ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-beta/Smad-induced growth arrest of prostate cells. Oncogene 25: 5591-5600. (Pubitemid 44387615)
42. Puri C, Chibalina MV, Arden SD, Kruppa AJ, Kendrick-Jones J, Buss F. (2010). Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis. Oncogene 29: 188-200.
43. Rahman A, Friedman DS, Goldstein LS. (1998). Two kinesin light chain genes in mice. Identification and characterization of the encoded proteins. J Biol Chem 273: 15395-15403.
44. Rahman-Roblick R, Hellman U, Becker S, Bader FG, Auer G, Wiman KG et al. (2008). Proteomic identification of p53-dependent protein phosphorylation. Oncogene 27: 4854-4859.
45. Reynisdottir I, Polyak K, Iavarone A, Massague J. (1995). Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 9: 1831-1845.
46. Ross S, Hill CS. (2008). How the Smads regulate transcription. Int J Biochem Cell Biol 40: 383-408. (Pubitemid 351241229)
47. Stambolic V, Woodgett JR. (1994). Mitogen inactivation of glycogen synthase kinase-3b in intact cells via serine 9 phosphorylation. Biochem J 303: 701-704. (Pubitemid 24325998)
48. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H et al. (2001). Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 61: 7388-7393. (Pubitemid 32995021)
49. Su SC, Tsai LH. (2011). Cyclin-dependent kinases in brain development and disease. Annu Rev Cell Dev Biol (in press).
50. Sutherland C, Leighton IA, Cohen P. (1993). Inactivation of glycogen synthase kinase-3b by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 296: 15-19. (Pubitemid 23344723)
51. Tomomura M, Morita N, Yoshikawa F, Konishi A, Akiyama H, Furuichi T et al. (2007). Structural and functional analysis of the apoptosis-associated tyrosine kinase (AATYK) family. Neuroscience 148: 510-521. (Pubitemid 47362500)
52. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J et al. (2008). Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 14: 681-687. (Pubitemid 351809551)
53. Tsai L-H, Delalle I, Caviness JVS, Chae T, Harlow E. (1994). p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371: 419-423. (Pubitemid 24302556)
54. Vagnoni A, Rodriguez L, Manser C, De Vos KJ, Miller CCJ. (2011). Phosphorylation of kinesin light chain-1 at serine-460 modulates binding and trafficking of calsyntenin-1. J Cell Sci 124: 1032-1042.
55. Wang H, Brautigan DL. (2002). A novel transmembrane ser/thr kinase complexes with protein phosphatase-1 and inhibitor-2. J Biol Chem 277: 49605-49612. (Pubitemid 36014401)
56. Wang H, Brautigan DL. (2006). Peptide microarray analysis of substrate specificity of the transmembrane SER/THR kinase KPI-2 reveals reactivity with CFTR and phosphorylase. Mol Cell Proteomics 5: 2124-2130. (Pubitemid 44817024)
57. Waters KM, Le Marchand L, Kolonel LN, Monroe KR, Stram DO, Henderson BE et al. (2009). Generalizability of associations from prostate cancer genome-wide association studies in multiple populations. Cancer Epidemiol Biomarkers Prev 18: 1285-1289.
58. Wozniak MJ, Allan VJ. (2006). Cargo selection by specific kinesin light chain 1 isoforms. EMBO J 25: 5457-5468. (Pubitemid 44847187)
59. Zhou S, Zawel L, Lengauer C, Kinzler KW, Vogelstein B. (1998). Characterization of human FAST-1, a TGF beta and activin signal transducer. Mol Cell 2: 121-127. (Pubitemid 128378973)